Abstract:OBJECTIVE: To investigate the correlation between breast cancer magnetic resonance imaging features and immune molecular subtypes.PATIENTS AND METHODS: A total of 129 breast cancer patients were selected as the research object. All the patients were diagnosed by histopathology. All of them had breast magnetic resonance imaging and examination data of immunohistochemical (IHC) ER. PR. HER-2. and Ki-67. The correlation of breast cancer magnetic resonance imaging features with different immune molecular subtypes was retrospectively analyzed.RESULTS: Breast cancer is divided into different molecular subtypes. There were 72 cases with Luminal A type (55.81%), 20 cases with Lu-minal B type (15.50%), 14 cases with HER-2+ type (HER-2 type for over-expression) (10.85%), 23 cases with TNBC type (ER, PR and HER-2 were negative) (17.84%). The magnetic resonance imaging features of breast cancer were included. the post-enhanced morphology, margins, internal enhancement features, time-signal intensity curve (TIC) and molecular subtype expression of lesions were significantly correlated with the immune molecular subtypes (C=0.602. 0.439, 0.350 and 0.407, p=0.000, 0.000, 0.006 and 0.000). Lesion morphology: Luminal A type was mainly oval, accounting for 76.39% (55/76). Luminal B type and HER-2+ type was mainly irregular, accounting for 75.00% (15/20) and 64.29% (9/14) respectively. TNBC type was mainly shown as lobulation, accounting for 60.87% (14/23). Margin of the lesion: Luminal A type was mainly smooth margin, accounting for 73.61% (53/72). Luminal B type and TNBC type was mainly irregular margin, accounting for 70.00% (14/20) and 56.52% (13/23) respectively. The margin of HER-2+ type was mainly spiculation. accounting for 64.29% (9/14). The internal enhancement features: Luminal A type were mainly even enhancement, accounting for 62.50% (45/72). Luminal B type and HER-2+ type were mainly heterogeneous enhancement, accounting for 65.00% (13/20) and 64.29% (9/14) respectively. TNBC type was mainly annular enhancement, accounting for 73.91% (17/23). TIC type: Luminal A type was mainly Type II, accounting for 66.67% (48/72). Luminal B, HER-2+ type and TNBC type was mainly Type HI. accounting for 70.00% (14/20), 64.29% (9/14) and 60.87% (14/23) respectively. The clinical signs include painless breast lumps, bloody breast discharge, and orange peel-like skin changes, nipple retraction and nipple elevation. There is no significant correlation between the above signs and the expression of molecular subtypes (C=0.014, 0.129, 0.154, 0.097 and 0.057. p=0.999, 0.533, 0.447, 0.747 and 0.935 respectively), the difference is not statistically significant (p>0.05).CONCLUSIONS: The characteristics of breast cancer magnetic resonance imaging was certainly correlated with the expression of immune molecular subtypes. The breast cancer molecular subtypes can be predicted by the imaging signs. which can provide valuable information for preoperative neoadjuvant treatment of breast cancer.

Differentiation Between Luminal A and B Molecular Subtypes of Breast Cancer Using Pharmacokinetic Quantitative Parameters with Histogram and Texture Features on Preoperative Dynamic Contrast-Enhanced Magnetic Resonance Imaging

Radiomic Analysis of Pharmacokinetic Heterogeneity Within Tumor Based on the Unsupervised Decomposition of Dynamic Contrast-Enhanced MRI for Predicting Histological Characteristics of Breast Cancer

Evaluation Of Background Parenchymal Enhancement And Histogram-Based Diffusion-Weighted Image In Determining The Molecular Subtype Of Breast Cancer

Molecular Imaging Using PET and SPECT for Identification of Breast Cancer Subtypes

Radiomic Analysis Reveals DCE-MRI Features for Prediction of Molecular Subtypes of Breast Cancer.

Dual-energy CT quantitative parameters for the differentiation of benign from malignant lesions and the prediction of histopathological and molecular subtypes in breast cancer

Association between quantitative parameters of DCE-MRI and molecular subtypes of breast cancer

Application of DCE-MRI radiomics signature analysis in differentiating molecular subtypes of luminal and non-luminal breast cancer

The Correlation of Quantitative and Semi-Quantitative Parameters Obtained from Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Histopathology in Human Breast Cancer

Discrimination Between Benign and Malignant Breast Lesions Using Volumetric Quantitative Dynamic Contrast-Enhanced MR Imaging.

Radiogenomic analysis of breast cancer: Dynamic contrast enhanced - Magnetic resonance imaging based features are associated with molecular subtypes

Correlation Between Pharmacokinetic Analysis of DCE-MRI and Breast Image Reporting and Data System (BIRADS) Classification.

Correlation of Dynamic Contrast-Enhanced MRI and Diffusion-Weighted MR Imaging with Prognostic Factors and Subtypes of Breast Cancers.

MRI and Pathological Features of Different Molecular Subtypes of Breast Cancers

A Clinically Feasible Method to Estimate Pharmacokinetic Parameters in Breast Cancer

Comparison of diffusion kurtosis imaging and dynamic contrast enhanced MRI in prediction of prognostic factors and molecular subtypes in patients with breast cancer

Diffusion-weighted Imaging Features of Breast Tumours and the Surrounding Stroma Reflect Intrinsic Heterogeneous Characteristics of Molecular Subtypes in Breast Cancer

DCE-MRI Texture Analysis with Tumor Subregion Partitioning for Predicting Ki-67 Status of Estrogen Receptor-Positive Breast Cancers.

Heterogeneity Of Tumor And Its Surrounding Stroma On Dce-Mri And Diffusion Weighted Imaging In Predicting Histological Grade And Lymph Node Status Of Breast Cancer

Correlation Study Between The Magnetic Resonance Imaging Features Of Breast Cancer And Expression Of Immune Molecular Subtypes

Comparison of Dynamic Contrast‐Enhanced MRI and Non‐Mono‐Exponential Model‐Based Diffusion‐Weighted Imaging for the Prediction of Prognostic Biomarkers and Molecular Subtypes of Breast Cancer Based on Radiomics